Articles On Adherium (ASX:ADR)

John Athanasiou, Red Leaf Securities BUY RECOMMENDATIONS Adherium (ADR)   Chart: Share price over the year ADR is a digital health solutions provider. It develops, makes and supplies a broad range of connected medical devices for respirator...

Global funding for telehealth companies surged in the March quarter as investors jumped on what will clearly be a trend for 2020. A total of $US788m ($1.3bn) was invested into this sector making it the top funded digital health segment in t...

New Zealand-based Adherium (ASX: ADR) is set to form a collaborative alliance with US-based HGE Health to remotely evaluate, treat and manage patients with severe asthma and chronic obstructive pulmonary disease. The respiratory device manu...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

  It’s Tuesday team. Here’s what’s going on in the world.   1.  US politician who invested in an ASX-listed medtech jailed for insider trading Australia’s corporate cop, the Australian Securities and Investments Commission (ASIC) has been a...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 136-odd small cap health stocks, 47 saw their share prices fall, 67 improved and 22 were flat. >> Scroll down for a table showing the performance of s...

The new-look ServTech is pushing its virtual reality technology into dentistry training, being paid $500,000 by a new client for VR dental software. The company changed its name to Vection (ASX:VR1) after buying a European software developm...

Air pollution is a growing problem that in recent days has reached our own backyard. Because of the bushfires in surrounding areas, Sydney’s air has been ranked the ninth worst in the world. It’s not the first time in history it’s happened...

Digital health company Adherium(ASX:ADR) has appointed Dr Peter Stratford as its CEO and Mike Motion at its Chief Commercial Officer.

HeraMED’s (ASX:HMD) foetal ultrasound heart rate monitor has got its long awaited green light to enter the US market and it has doubled in just a few days. The US Food and Drug Administration has approved its 510(k) application meaning it c...

Here’s our fortnightly wrap of the major small cap health stock winners and losers. For the second fortnight in a row, Novita Healthcare (ASX:NHL) is the best-performing ASX small cap healthcare stock, up 72 per cent to 7.8c. Novita was the...

At the close of trading session on 24th October 2019, the benchmark index, i.e. S&P/ ASX 200 closed at 6,693.6 points with a rise of 20.5 points. Designing a portfolio for the purpose of making investment requires a meticulous approach....

On Stockhead today: Aussie small caps trying to tackle the opioid crisis, which car manufacturers will survive the EV revolution, Barry FitzGerald looks at upcoming juniors, and how South Australian small caps are putting themselves back on...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Australian respiratory medical device company Adherium (ASX:ADR) has announced a new strategic data-based initiative with Summatix.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...

Adherium (ASX: ADR) shares have risen 19 per cent this morning following news the asthma monitoring firm had received clearance to sell its devices in the US. The Food and Drug Administration (FDA) granted 510(k) clearance for its Hailie se...